Answers are grounded in this paper and cite their sources.
Recently, two studies have claimed that cholesterol lowering drugs, particularly statins, protect against age related maculopathy. 1 2 The end stage of this progressive retinal disorder is the commonest cause of untreatable blindness in elderly people in Western societies, and its prevalence is expected to rise with the ageing of the population.Thus, preventing this disorder would have an enormous public health impact.3 The above mentioned studies used interview data on drug use and had a low statistical power.We therefore tested the hypothesis that cholesterol lowering drugs protect against age related maculopathy in a large cohort study with cumulative exposure measured. Participants, methods, and resultsThis investigation was part of the Rotterdam study, a population based cohort study of people aged 55 years and more.After the baseline phase from 1990 to 1993, two follow up examinations were performed at mean intervals of 2 and 6.5 years.Of all the subjects at risk of age related maculopathy, 4822 (83%) participated at follow up.A diagnosis of age related maculopathy was based on stereoscopic colour fundus transparencies graded according to the international classification system.4 The incidence of the disorder was defined as the development of soft distinct drusen with pigmentary irregularities, indistinct drusen, or the end stages of atrophic or neovascular age related macular degeneration.A register of prescriptions filled by local pharmacies provided continuous data on use of cholesterol lowering drugs.These data were available for 99% of the cohort from 1 January 1991 onwards.We used Cox proportional hazards regression analysis to calculate hazard ratios, with age in days as the time axis to ensure optimal controlling for age.Cumulative exposure to drugs was represented as a time dependent covariate and was analysed both as a dichotomous and a categorical variable.The model compared each incident case of age related maculopathy with all subjects in the cohort who were alive and free of the disorder at the age when the case of maculopathy was diagnosed.5 During 26 781 person years of follow up, 457 patients used cholesterol lowering drugs for one or more days, and 419 cases of incident age related maculopathy were observed.Use of cholesterol lowering drugs at any time, defined as a binary variable, was not associated with the incidence of age related maculopathy (hazard ratio 1.0 (95% confidence interval 0.7 to 1.5)).Compared with patients who had never used cholesterol lowering drugs, cumulative exposure for less than one month, for one month to a year, or for more than a year did not have a protective effect on the risk of maculopathy (see table ).Additional adjustment for body mass index, hypertension, smoking, and peripheral arterial disease (ankle:arm index < 0.9) did not change the association.When we performed the same analysis with progression of age related maculopathy as the outcome variable, we obtained the same results.
No takes yet. Share an insight, caveat, or question.
R. van Leeuwen (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: